The application of immune-based therapies to augment the anti-tumor immune response following autologous and allogeneic blood or marrow transplantation (BMT) has dramatically increased over the past several years. Reconstitution of the immune system following BMT, graft-versus-host disease (GVHD), and post-grafting immunosuppression may modify any immunotherapeutic approach. The need to carefully evaluate, and monitor the immune response in this setting has become Increasingly apparent In addition, recent studies indicate that the in vivo transfer of immune reactive cells expanded ex vivo can augment the anti-tumor effect of BMT. The principal objectives of the Immunologic Monitoring and C ell Processing Core are to provide state-of-the-art immunologic techniques to characterize and quantify human immune responses in support of the research projects of this program project grant and to provide the cell processing expertise to support the clinical laboratory requirements of this program project grant. While there is great diversity in the therapeutic modalities being evaluated, most areas strongly overlap with regard to analysis and characterization of the immune response. A wide-variety of techniques that enumerate and characterize antigen-specific T cells, assess their functional behavior ex vivo, evaluate the diversity of the T cell response as well as expand T cell populations ex vivo are currently available to the research projects within this Program Project. Therefore, the specific aims of this Core are to: 1. Provide technical expertise and conduct assays to monitor and characterize the immune response. 2. Establish standard operating procedures and quality control for all immunological assays. 3. Provide technical support to identify and develop assays specific for all projects. 4. Serve as a repository for donor and patient peripheral blood lymphocytes. 5. Immunologically activate and expand ex vivo patient-derived marrow infiltrating lymphocytes (aMILs). 6. Serve as the quality and regulatory support for the clinical laboratory component of the aMILs trials.
The Immunological Monitoring and Cell Processing Core supports all projects within this program project grant by providing state-of-the-art immune assays as well as the ability to expand Immunologically relevant T cells for clinical adoptive immunotherapy.
|Kanakry, Christopher G; O'Donnell, Paul V; Furlong, Terry et al. (2014) Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 32:3497-505|
|Fuchs, Ephraim J (2014) Transplantation tolerance: from theory to clinic. Immunol Rev 258:64-79|
|Showel, Margaret M; Brodsky, Robert A; Tsai, Hua-Ling et al. (2014) Isolated clonal cytogenetic abnormalities after high-dose therapy. Biol Blood Marrow Transplant 20:1130-8|
|Fu, Juan; Malm, Ian-James; Kadayakkara, Deepak K et al. (2014) Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 74:4042-52|
|Goswami, M; Hensel, N; Smith, B D et al. (2014) Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia 28:1167-70|
|Agarwal, Jasmin R; Wang, Qiuju; Tanno, Toshihiko et al. (2014) Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma. Mol Cancer Ther 13:1873-81|
|Eapen, Mary; O'Donnell, Paul; Brunstein, Claudio G et al. (2014) Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant 20:1485-92|
|Zeidan, Amer M; Forde, Patrick M; Symons, Heather et al. (2014) HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20:314-8|
|Gerber, Jonathan M; Gucwa, Jessica L; Esopi, David et al. (2013) Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget 4:715-28|
|Kanakry, Jennifer A; Kasamon, Yvette L; Bolanos-Meade, Javier et al. (2013) Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19:1514-7|
Showing the most recent 10 out of 393 publications